Lipocine (LPCN) CEO Mahesh Patel Buys $131K of Stock
Mahesh Patel purchased shares of Lipocine Inc., indicating confidence in the company’s future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mahesh Patel, Chief Executive Officer at Lipocine Inc. ($LPCN), bought 52,781 shares at an average price of $2.49, worth about $131,424.69, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LPCN is down 0.8% after 1 week, down 16.9% after 1 month and down 37.4% to date (from the $2.49 close on Jun 29, 2026).
LPCN
Lipocine Inc.
Key Points
- On June 29, 2026, CEO Mahesh Patel bought 52,781 shares of Lipocine Inc. at $2.49 each, totaling about $131,425.
- The stock trades near the 52-week low of $1.81, well below its high of $12.37, showing a significant dip in value.
- HC Wainwright & Co. maintains a Neutral rating with a target price of $4.00, suggesting potential for growth in the stock.
Get $LPCN trade alerts by text
We text you when insiders, Congress or big funds trade $LPCN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Lipocine Inc. alert may contain errors. Disclosures
CEO's Recent Share Purchase
On June 29, 2026, Mahesh Patel, the Chief Executive Officer of Lipocine Inc. (LPCN) on the NasdaqCM, bought 52,781 shares at a price of $2.49 each. This purchase totaled approximately $131,425. It reflects Patel's confidence in the company's future prospects.
How Lipocine Inc. Stock Has Traded
Lipocine's shares are currently trading at $2.56, close to the 52-week low of $1.81. The stock has seen a significant decline over the past year, with a high of $12.37. This current price suggests that the shares are undervalued compared to their previous highs, which could attract more investor attention.
Analysts Set New Price Targets
On September 21, 2026, HC Wainwright & Co. reiterated a Neutral rating on Lipocine with a price target of $4.00. The analysts' consensus indicates there might be room for the stock to recover given its current valuation and the company's development pipeline.
About Lipocine Inc.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drug delivery technologies. It specializes in treatments for hormone replacement and various neurological disorders, aiming to improve patient outcomes through its proprietary formulations.
What's Next for Lipocine?
Investors will be watching for Lipocine's next earnings report on August 14, 2025. The recent insider purchase and analyst support may signal potential changes in market sentiment as the company advances its drug development efforts.
Related Filing Alerts
Source: Mahesh Patel's Form 4 filing on $LPCN (Jun 29, 2026). Find the original filing: LPCN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts